Top

Published in:

01-04-2016 | Original Paper

Effect of aflibercept in patients with age-related macular degeneration

Authors: Hiroko Okuma, Tatsuya Mimura, Mari Goto, Yuko Kamei, Maiko Yoshida, Aki Kondo, Masao Matsubara

Published in: International Ophthalmology | Issue 2/2016

Abstract

The purpose of this study was to evaluate the efficacy of standard induction therapy with intravitreal aflibercept (IVA) in patients with exudative age-related macular degeneration (AMD) at 6 months after completion of induction therapy. Eleven eyes with typical AMD (tAMD) and 13 eyes with polypoidal choroidal vasculopathy (PCV) received three monthly doses of IVA (2 mg/0.05 ml in weeks 0, 4, and 8) for treatment of exudative AMD. Best-corrected visual acuity (BCVA) was measured, and optical coherence tomography was performed at baseline and at each monthly visit until 6 months after IVA. Treatment failure was defined as persistent or recurrent AMD that presented with cystoid macular edema, serous retinal detachment, and pigment epithelium detachment. Mean logMAR BCVA was improved from 0.62 ± 0.46 at baseline to 0.54 ± 0.43 at 6 months after IVA (p < 0.05). The success rate was 95.8 % at 3 months and 75.0 % at 6 months after IVA. Failure of IVA was positively associated with the absence of PVD before treatment (r = 0.35) and with the AMD type (tAMD, r = 0.43) by univariate analysis. Cox proportional hazards analysis demonstrated that the absence of PVD before treatment was associated with an increased risk of failure of IVA (OR = 33.17, p = 0.0219). Three months of induction IVA achieved a high success rate in patients with AMD monitored for up to 6 months. Factors associated with failure of IVA were the absence of PVD and the presence of tAMD. Accordingly, continuation of IVA following induction therapy may be beneficial to manage AMD in patients with tAMD or those without PVD.

VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, McCarty CA (2000) The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 107(8):1593–1600CrossRefPubMed

Weih LM, VanNewkirk MR, McCarty CA, Taylor HR (2000) Age-specific causes of bilateral visual impairment. Arch Ophthalmol 118(2):264–269CrossRefPubMed

Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144(1):15–22CrossRefPubMed

Silva RM, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG (2005) Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 243(10):973–979CrossRefPubMed

Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A, Yoshimura N (2007) Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 144(1):7–14CrossRefPubMed

Kokame GT, Yeung L, Lai JC (2010) Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 94(3):297–301CrossRefPubMed

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, VIEW 1 and VIEW 2 Study Groups (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537–2548CrossRefPubMed

Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121(1):193–201CrossRefPubMed

Ogura Y, Terasaki H, Gomi F, Yuzawa M, Iida T, Honda M, Nishijo K, Sowade O, Komori T, Schmidt-Erfurth U, Simader C, Chong V, VIEW 2 Investigators (2015) Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol 99(1):92–97CrossRefPubMedPubMedCentral

10.

Trichonas G, Kaiser PK (2013) Aflibercept for the treatment of age-related macular degeneration. Ophthalmol Ther 2(2):89–98CrossRefPubMedPubMedCentral

11.

Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF (2012) Pharmacokinetic rationale for dosing every 2 versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 32(3):434–457PubMed

12.

Thylefors B, Chylack LT Jr, Konyama K, Sasaki K, Sperduto R, Taylor HR, West S, WHO Cataract Grading Group (2002) A simplified cataract grading system. Ophthalmic Epidemiol 9(2):83–95CrossRefPubMed

13.

Gharbiya M, Iannetti L, Parisi F, De Vico U, Mungo ML, Marenco M (2014) Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int 2014:273754CrossRefPubMedPubMedCentral

14.

Noma H, Mimura T, Eguchi S (2013) Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol 131(2):160–165CrossRefPubMed

15.

Noma H, Shimada K, Mimura T (2013) Visual function after pars plana vitrectomy in macular edema with branch retinal vein occlusion. Int Ophthalmol 33(3):227–236CrossRefPubMed

16.

Goldenberg DT, Trese MT (2019) Pharmacologic vitreodynamics and molecular flux. Dev Ophthalmol 44:31–36CrossRef

17.

Shah SS, Denham LV, Elison JR, Bhattacharjee PS, Clement C, Huq T, Hill JM (2010) Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol 5(1):75–93CrossRefPubMedPubMedCentral

18.

Yoshida A, Furukawa H, Delori FC, Bursell SE, Trempe CL, McMeel JW (1984) Effect of vitreous detachment on vitreous fluorophotometry. Arch Ophthalmol 102(6):857–860CrossRefPubMed

19.

Laude A, Tan LE, Wilson CG, Lascaratos G, Elashry M, Aslam T, Patton N, Dhillon B (2010) Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics. Prog Retin Eye Res 29(6):466–475CrossRefPubMed

20.

Prager TC, Chu HH, Garcia CA, Anderson RE (1982) The influence of vitreous change on vitreous fluorophotometry. Arch Ophthalmol 100(4):594–596CrossRefPubMed

21.

Goldenberg DT, Giblin FJ, Cheng M, Chintala SK, Trese MT, Drenser KA, Ruby AJ (2011) Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes. Retina 31(2):393–400CrossRefPubMedPubMedCentral

22.

Silva PS, Singh RJ, Bakri SJ, Lising RS, Santiago DE, Uy HS (2009) Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection. Ocul Immunol Inflamm 17(3):216–220CrossRefPubMed

23.

Geck U, Pustolla N, Baraki H, Atili A, Feltgen N, Hoerauf H (2013) Posterior vitreous detachment following intravitreal drug injection. Graefes Arch Clin Exp Ophthalmol 251(7):1691–1695CrossRefPubMedPubMedCentral

24.

Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331(22):1480–1487CrossRefPubMed

25.

Itakura H, Kishi S, Kotajima N, Murakami M (2004) Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. Ophthalmology 111(10):1880–1884CrossRefPubMed

26.

Noma H, Funatsu H, Mimura T, Hori S (2008) Changes of vascular endothelial growth factor after vitrectomy for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 18(6):1017–1019PubMed

27.

Yamashiro K, Tomita K, Tsujikawa A, Nakata I, Akagi-Kurashige Y, Miyake M, Ooto S, Tamura H, Yoshimura N (2012) Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 154(1):125–136CrossRefPubMed

28.

Aflibercept (2008) AVE 0005, AVE 005, AVE0005, VEGF Trap—Regeneron, VEGF Trap (R1R2). VEGF Trap-Eye. Drugs RD 9(4):261–269

29.

Trichonas K, Kaiser PK (2013) Aflibercept for the treatment of age-related macular degeneration. Ophthalmol Ther 2(2):89–98CrossRefPubMedPubMedCentral

Title: Effect of aflibercept in patients with age-related macular degeneration
Authors: Hiroko Okuma
Tatsuya Mimura
Mari Goto
Yuko Kamei
Maiko Yoshida
Aki Kondo
Masao Matsubara
Publication date: 01-04-2016
Publisher: Springer Netherlands
Published in: International Ophthalmology / Issue 2/2016
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-015-0089-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of aflibercept in patients with age-related macular degeneration

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

Two masquerade presentations of retinoblastoma

Ocular adnexal and orbital amyloidosis: a case series and literature review

Age-based analysis of choroidal thickness and choroidal vessel diameter in primary open-angle glaucoma

Treatment of massive subretinal hematoma associated with age-related macular degeneration using vitrectomy with intentional giant tear

Systemic oxygen therapy versus oral enalapril for treatment of diabetic macular ischemia: a randomized controlled trial

Combined pars plana vitrectomy–scleral buckle versus pars plana vitrectomy for proliferative vitreoretinopathy